Logo

Hit Tumors* Hard With TheraSphere

Interventional Oncology / Cancer Therapies & Ablation / TheraSphere
The only FDA approved Y-90 treatment for HCC.

The only FDA approved Y-90 treatment for HCC

TheraSphere now has FDA pre-market approval after 20 years as a humanitarian exemption device (HDE), making TheraSphere the only Y-90 therapy indicated for Hepatocellular Carcinoma (HCC).  The FDA has also granted Breakthrough Device designation for TheraSphere treatment for patients with glioblastoma.

TheraSphere has not been approved for treatment of patients with glioblastoma

Become An Authorized User ›
 
Dose Matters. Power Embedded Within.

Dose Matters.
Power Embedded Within.

TheraSphere is a highly potent Y-90 treatment that allows for precise and personalized dosing to directly attack HCC liver tumors with less damage to healthy tissue– improving tumor response and patient outcomes2-3

Learn Why Dose Matters ›
 
The EPOCH Trial background with vial and single glass sphere.

The EPOCH Trial

A Phase III Clinical Trial Evaluating TheraSphere in Patients with Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy.

Learn More › 

CAUTION: In the US, Therasphere is under an investigational device exemption for treatment of patients with metastatic colorectal cancer. The safety and effectiveness for this treatment has not been established.

 

Proven. Personalized. Precise.
line-break

Strike first with three distinct advantages. We have a proven therapy to fight primary liver cancer.4 We deploy a custom personalized dose to extend life, to improve life. We act with expert precision.

 
patient image.

Your patients are fighting for more than their survival. They’re fighting for their quality of life. TheraSphere is uniquely able to help you strike first on both fronts.

glass beads image.

Glass Matters With Y-90

Give your patients a fighting chance with TheraSphere Y-90 Glass Microspheres. These precision-manufactured glass microspheres are the most powerful radiation therapy on the market.
 

1. Pasciak, A. S., Abiola, G., Liddell, R. P., Crookston, N., Besharati, S., Donahue, D., Thompson, R. E., Frey, E., Anders, R. A., Dreher, M. R., & Weiss, C. R. (2019). The number of microspheres in Y90 radioembolization directly affects normal tissue radiation exposure. European Journal of Nuclear Medicine and Molecular Imaging, 47(4), 816–827. https://doi.org/10.1007/s00259-019-04588-x. 

2. Garin E, Tselikas L, Guiu B et al. Personalized versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01):a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021, 6: 17-29 

3. Lam, M., Garin, E., Maccauro, M. et al. A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging (2022). https://doi.org/10.1007/s00259-022-05774-0

4. Salem R, Gabr A, Riaz A, et al. Institutional decision to adopt Y-90 as primary treatment for HCC informed by a 1,000-patient 15-year experience. Hepatology. 2017 Dec 1. 

*Refers to HCC or associated tumors  

 
Top